Monitor the completion of ADVANCED-2 enrollment by year-end 2026 and the interim THRIVE-3 results expected in Q4 2026, as these are key catalysts for TARA-002 and IV Choline Chloride programs. The $8.75M manufacturing asset acquisition signals preparation for commercial launch but adds to cash burn.
Price Chart
Executive Summary
Protara Therapeutics reported Q3 2026 results: net loss of $21.7M ($0.35 per share) vs $13.3M loss ($0.31) a year ago, with R&D expenses rising to $16.8M from $9.6M. The company is on track to complete enrollment of the BCG-Unresponsive ADVANCED-2 trial by year-end 2026 and expects to initiate a rolling BLA submission for TARA-002 in LMs in 2H 2027. Cash of $143M is expected to fund operations into 2028.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $21.7 million, or $0.35 per share, compared to net loss of $13.3 million, or $0.31 per share, in Q3 2025
- Cash, cash equivalents and investments of approximately $143 million as of September 30, 2026
- Expects to complete enrollment of BCG-Unresponsive registrational cohort of ADVANCED-2 trial by year-end 2026
- Enrollment in STARBORN-1 trial now expected to complete in early Q1 2027; rolling BLA submission for TARA-002 in LMs expected in 2H 2027
- Completed enrollment of THRIVE-3 Phase 2b dosing cohort; interim results expected by year-end 2026
- Entered into asset purchase agreement with Novex Innovations for TARA-002 manufacturing-related assets for $8.75 million
- R&D expenses increased to $16.8 million from $9.6 million year-over-year
- Cash expected to support planned operations into 2028
Financial Impact
Net loss widened to $21.7M from $13.3M; cash burn increased with R&D spending up $7.2M YoY; $8.75M asset purchase for manufacturing
Risk Factors
- Net loss widening year-over-year with no revenue; cash burn rate increasing
- Clinical trial enrollment timelines for STARBORN-1 slipped from Q4 2026 to early Q1 2027
- Pre-revenue clinical-stage company dependent on successful trial outcomes and regulatory approvals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-116607 |
| Document: ea0309567-8k_protara.htm | 0001213900-26-116607 |
| Document: 0001213900-26-116607-index-headers.html | 0001213900-26-116607 |
| Document: 0001213900-26-116607-index.html | 0001213900-26-116607 |
| Document: 0001213900-26-116607.txt | 0001213900-26-116607 |
| 8-K Data (Synthetic) | 0001213900-26-116607 |
Track record
13 reports on TARA
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.50% at T+60 after the May 26, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
- Nov 6, 202610d ago 8-K Neutral 4/10 Viewing No price data
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
- Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
- May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
- May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
- May 13, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers